Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas

2017 ◽  
Vol 31 ◽  
pp. 45-49 ◽  
Author(s):  
Vedran Kardum ◽  
Valentina Karin ◽  
Mislav Glibo ◽  
Anita Skrtic ◽  
Tamara Nikuseva Martic ◽  
...  
Keyword(s):  
High Grade ◽  
Ovarian Carcinomas

MOLECULAR AND GENETIC SUBTYPES OF OVARIAN CANCER: PROSPECTS FOR FURTHER STUDIES

2019 ◽  
Vol 65 (1) ◽  
pp. 56-62
Author(s):  
Alisa Villert ◽  
Larisa Kolomiets ◽  
Natalya Yunusova ◽  
Yevgeniya Fesik
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Molecular Subtypes ◽  
Survival Rates ◽  
Consensus Algorithm ◽  
Histopathological Diagnosis ◽  
Low Grade ◽  
High Grade ◽  
Ovarian Carcinomas ◽  
Genetic Subtypes

High-grade ovarian carcinoma is a histopathological diagnosis, however, at the molecular level, ovarian cancer represents a heterogeneous group of diseases. Studies aimed at identifying molecular genetic subtypes of ovarian cancer are conducted in order to find the answer to the question: can different molecular subgroups influence the choice of treatment? One of the achievements in this trend is the recognition of the dualistic model that categorizes various types of ovarian cancer into two groups designated high-grade (HG) and low-grade (LG) tumors. However, the tumor genome sequencing data suggest the existence of 6 ovarian carcinoma subtypes, including two LG and four HG subtypes. Subtype C1 exhibits a high stromal response and the lowest survival. Subtypes C2 and C4 demonstrate higher number of intratumoral CD3 + cells, lower stromal gene expression and better survival than sybtype C1. Subtype C5 (mesenchymal) is characterized by mesenchymal cells, over-expression of N-cadherin and P-cadherin, low expression of differentiation markers, and lower survival rates than C2 and C4. The use of a consensus algorithm to determine the subtype allows identification of only a minority of ovarian carcinomas (approximately 25%) therefore, the practical importance of this classification requires additional research. There is evidence that it makes sense to randomize tumors into groups with altered expression of angiogenic genes and groups with overexpression of the immune response genes, as in the angiogenic group there is a comparative superiority in terms of survival. The administration of bevacizumab in the angiogenic group improves survival, while the administration of bevacizumab in the immune group even worsens the outcome. Molecular subtypes with worse survival rates (proliferative and mesenchymal) also benefit most from bevacizumab treatment. This review focuses on some of the advances in understanding molecular, cellular, and genetic changes in ovarian carcinomas with the results achieved so far regarding the formulation of molecular subtypes of ovarian cancer, however further studies are needed.

scholarly journals An Emerging Anti-p16 Antibody-BC42 Clone as an Alternative to the Current E6H4 for Use in the Female Genital Tract Pathological Diagnosis: Our Experience and a Review on p16ink4a Functional Significance, Role in Daily-Practice Diagnosis, Prognostic Potential, and Technical Pitfalls

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 713
Author(s):  
Giuseppe Angelico ◽  
Angela Santoro ◽  
Frediano Inzani ◽  
Patrizia Straccia ◽  
Saveria Spadola ◽  
...  
Keyword(s):  
Female Genital Tract ◽  
Daily Practice ◽  
Cervical Squamous Cell Carcinoma ◽  
High Grade ◽  
The Novel ◽  
Medical Systems ◽  
Ovarian Carcinomas ◽  
Study Results ◽  
Diagnostic Applications ◽  
Gynecologic Neoplasms

Background: To date, useful diagnostic applications of p16 IHC have been documented in gynecological pathology both for HPV-related and non-HPV-related lesions. In the present article, we reported our experience with the novel anti-p16 INK4a antibody (clone BC42), whose expression was tested across all different gynecologic neoplasms; we also compared it to the traditional E6H4 clone. Moreover, we discussed and explored all the diagnostic applications of p16 IHC in gynecologic pathology. Methods: Consultation cases covering a 5-year period (2016–2020) regarding gynecological neoplastic and non-neoplastic lesions in which immunohistochemistry for p16, clone E6H4 was originally performed, were retrospectively retrieved from the files of our institution. Immunohistochemical staining for p16ink4a (BC42) [Biocare Medical group-Paceco USA; Bioptica Milan] and p16ink4a (E6H4) [Ventana Medical Systems-Arizona USA; Roche] was performed by using the Ventana automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA). The immunostaining pattern was defined as negative, focal/patchy, or diffuse. Results: A total of 196 cases, represented by 36 high-grade SIL/CIN3 of the uterine cervix, 30 cervical adenocarcinomas, 22 cervical squamous cell carcinoma, 70 endometrial carcinomas, 25 high grade serous ovarian carcinomas, 6 uterine adenomatoid tumors, and 10 uterine leiomyosarcomas were included in this study. Results showed concordant staining quality of both clones on all tested neoplastic tissues. Conclusions: The novel anti-p16 antibody (BC42 clone) appeared as an alternative to the current E6H4 for use in gynecological neoplasms, offering similar levels of positivity and equally reliable staining results.

scholarly journals Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women

2019 ◽  
Vol 38 (2) ◽  
pp. 157-170 ◽  
Author(s):  
Anne M. Mills ◽  
Lauren C. Peres ◽  
Alice Meiss ◽  
Kari L. Ring ◽  
Susan C. Modesitt ◽  
...  
Keyword(s):  
African American ◽  
African American Women ◽  
High Grade ◽  
Ovarian Carcinomas ◽  
American Women ◽  
Regulatory Molecule

Abstract 4878: The fallopian tube is the origin of high-grade serous ovarian carcinomas in a mouse model

2012 ◽  
Author(s):  
Jaeyeon Kim ◽  
Donna M. Coffey ◽  
Chad J. Creighton ◽  
Zhifeng Yu ◽  
Shannon M. Hawkins ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fallopian Tube ◽  
High Grade ◽  
Ovarian Carcinomas

Abstract 749: Multi-layer molecular characterization of high grade serous ovarian carcinomas

2019 ◽  
Author(s):  
Robert L. Hollis ◽  
Alison M. Meynert ◽  
Michael Churchman ◽  
Tzyvia Rye ◽  
Patricia Roxburgh ◽  
...  
Keyword(s):  
Molecular Characterization ◽  
High Grade ◽  
Ovarian Carcinomas

scholarly journals Ultrasound, macroscopic and histological features of serous epithelial ovarian carcinomas

2020 ◽  
pp. ijgc-2020-001473
Author(s):  
Paola Romeo ◽  
Damiano Arciuolo ◽  
Maria Cristina Moruzzi ◽  
Francesca Moro
Keyword(s):  
Ovarian Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Ovarian Carcinomas ◽  
Histological Features ◽  
Serous Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinomas

We present a video showing two cases of serous epithelial ovarian carcinomas. The first video shows clinical, ultrasound, macroscopic, and histological features of a patient with high grade serous ovarian carcinoma. The second video presents clinical, ultrasound, macroscopic, and histological features of a patient with low grade serous ovarian carcinoma.

scholarly journals Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas

2009 ◽  
Vol 18 (8) ◽  
pp. 2256-2261 ◽  
Author(s):  
P. M. Grimley ◽  
R. K. Matsuno ◽  
P. S. Rosenberg ◽  
D. E. Henson ◽  
A. M. Schwartz ◽  
...  
Keyword(s):  
Low Grade ◽  
High Grade ◽  
Ovarian Carcinomas

scholarly journals High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

2010 ◽  
Vol 23 (10) ◽  
pp. 1316-1324 ◽  
Author(s):  
Michael H Roh ◽  
Yosuf Yassin ◽  
Alexander Miron ◽  
Karishma K Mehra ◽  
Mitra Mehrad ◽  
...  
Keyword(s):  
High Grade ◽  
Ovarian Carcinomas ◽  
Pax2 Expression
Sign in / Sign up

Export Citation Format

Share Document